Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2015

SEQUENOM, INC.

(Exact name of registrant as specified in its charter)



Delaware	000-29101	77-0365889
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)



3595 John Hopkins Court, San Diego, CA		92121
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 202-9000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On September 18, 2015, William J. Welch resigned as our President and Chief Executive Officer, effective immediately, and also resigned as a member of our Board of Directors, effective immediately.

(c) In connection with Mr. Welch’s resignation, on September 19, 2015, our Board of Directors appointed Dirk van den Boom, Ph.D., age 46, to the position of interim President and Chief Executive Officer, effective immediately. Dr. van den Boom will also retain his title as Chief Scientific and Strategy Officer, a position he has held since June 2014. From December 2012 through June 2014, Dr. van den Boom served as our Executive Vice President, Research and Development and Chief Technology Officer. Prior to that, he had served as our Senior Vice President of Research and Development since August 2010 and as our Vice President, Research and Development from October 2009 through August 2010. Dr. van den Boom joined us in 1998 in our Hamburg offices, subsequently serving in various management roles within our research and development department. Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry.

In connection with Dr. van den Boom’s appointment as interim President and Chief Executive Officer, on September 19, 2015, our Board of Directors approved an increase in Dr. van den Boom’s annual base salary from $475,000 to $550,000, which is an amount equivalent to Mr. Welch’s annual base salary at the time of his resignation. No other changes have been made to Dr. van den Boom’s compensation.

The press release announcing Dr. van den Boom’s promotion and Mr. Welch’s resignation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.



Item 9.01	Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release of Sequenom, Inc. dated September 21, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




	SEQUENOM, INC.

Dated: September 24, 2015	By:	/s/ Jeffrey D. Linton
	Name:	Jeffrey D. Linton
	Title:	Senior Vice President, General Counsel

FOR IMMEDIATE RELEASE

Sequenom Contacts:

Carolyn Beaver Rachel Kennedy

Senior Vice President and Chief Financial Officer Media Contact

Sequenom, Inc. inVentiv Health PR Group

858-202-9028 858-449-9575

investorrelations@sequenom.com rachel.kennedy@inventivhealth.com

Sequenom Announces Appointment of Dirk van den Boom as Interim President and CEO

SAN DIEGO, Calif. - September 21, 2015 - Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today the appointment of Dirk van den Boom, Ph.D. to the position of interim President and Chief Executive Officer. Dr. van den Boom succeeds William J. Welch following his resignation from that role, and as a director, to pursue other interests. In addition, Dr. van den Boom will continue to serve as Sequenom’s Chief Scientific and Strategy Officer.

Prior to his appointment as Interim President and CEO, Dr. van den Boom served as Chief Scientific and Strategy Officer since June 2014, and before that as Executive Vice President, Research and Development and Chief Technology Officer beginning in December 2012. Dr. van den Boom joined Sequenom in 1998 at the Company’s Hamburg office, subsequently serving in various management roles of increasing responsibility.

“We are excited for Dirk to take on the role of interim President and Chief Executive Officer, and believe that he is well positioned to lead our key strategic initiatives to develop and commercialize innovative products and services at Sequenom,” said Kenneth F. Buechler, Ph.D., Chairman of the Board of Directors. “We are confident that he will successfully lead our efforts to capitalize on our company’s future growth opportunities and goals. We thank Bill for his efforts for the Company and wish him well in future endeavors.”

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Sequenom’s filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K, its most recent Quarterly Reports on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Sequenom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

###

Sequenom, Inc. (NASDAQ:SQNM)
Historical Stock Chart
From May 2024 to Jun 2024